美国匹兹堡大学鲁兴华教授来校合作交流
- 发布时间：
- 2019-08-13
- 文章标题：
- 美国匹兹堡大学鲁兴华教授来校合作交流
- 内容：
报告题目：From Big Data to Bedside (BD2B): Towards AI-Based Clinical Decision Support for Precision Oncology
报告时间：2019年8月13日，星期二，上午 10:00-11:00
报告地点：数学楼2-3会议室
报告人: Prof. Xinghua Lu (鲁兴华), University of Pittsburgh
Abstract:
Cancer is mainly caused by somatic genome alterations that perturb cellular signaling pathways, and it is anticipated that precisely targeting patient-specific genomic alterations of individual tumors (precision oncology) will lead to more effective therapies. However, while genome-scale data from an individual patient can be readily obtained to guide contemporary molecularly targeted therapies, only a small fraction (< 10%) of all patients benefit from current precision oncology approach, and majority of patient are treated by standard of cares following current guide lines, which are not personalized. In this presentation, I will discuss different artificial intelligence technologies that can advance precision oncology, including causal inference methods for revealing the disease mechanisms of each individual tumor, causal network methods for discovering cancer pathways, and deep learning methods to infer the state of signaling machinery of tumor cells. I will further discuss how information derived from such analyses can be used to guide personalized application of anti-cancer drugs and present our results from pre-clinical studies.
报告人简介：
鲁兴华教授是匹兹堡大学生物医学信息系终身教授；匹兹堡大学癌症中心数据科学家；美国国立大数据到知识（Big Data to Knowledge）中心项目负责人。其课题组主要开发人工智能方法促进基础研究，转化医学，和临床决策支持。课题组目前把因果方法学，贝叶斯因果网络，深度学习应用到癌症的基础和转化研究。鲁兴华教授有广泛的生物医学科研经验，贯穿基础，临床，人工智能，信息学。 他的科研成果发表在多领域的主流杂志：《Bioinformatics》,《Genome Biology》, 《Molecular Systems Biology》,《Science Signaling》，《Cancer Cell》，《Cancer Research》等。过去十年内，他的课题组得到了过多项NIH课题资助。鲁教授拥有丰富的产学研开发经验，获UPMC超过300万美元的初期投资，是全方位的临床医学，基础医学，及人工智能的科研专家。目前，他的课题组获得匹兹堡大学医学中心（UPMC）的资助，开发指导肿瘤免疫学治疗的人工智能产品。
